Therapeutic Vaccines Market by Type and Geography - Forecast and Analysis 2020-2024

“The Therapeutic Vaccines Market study is a comprehensive report with in-depth qualitative and quantitative research evaluating the current scenario and analyzing the growth of USD 3.78 billion and CAGR of 43% by segment Type and Geography during the forecast period 2019 to 2024” 

Furthermore, this report extensively covers the smart home appliances market segmentation by type (cancer vaccines, infectious diseases vaccines, Neurological diseases vaccines, autoimmune diseases vaccines, and other diseases vaccines) and geography (North America, Europe, Asia, and ROW). The market report also offers information on several market vendors, includingAdvantagene Inc., Aimmune Therapeutics Inc., Amgen Inc., Gilead Sciences Inc., Immune Response BioPharma Inc., Inovio Pharmaceuticals Inc., Merck & Co. Inc., Novartis AG, Sanpower Group Co. Ltd., and SOTIO AS.

Download the Report Sample to Unlock the Smart Room Heater Market Size for the Forecast Period and Other Important Statistics 

Parent Market Analysis

Technavio categorizes the Therapeutic Vaccines Market as a part of the Health Care industry within the Pharmaceuticals industry. Our Technavio research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the forecast year.

Therapeutic Vaccines Market: Key Drivers, Trends, and Challenges

Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic's impact on the therapeutic vaccines industry. The holistic analysis of the drivers will help deduce end goals and refine marketing strategies to gain a competitive edge. 

Key Therapeutic Vaccines Market Driver

One of the key factors driving growth in the market is the rising incidence and prevalence of diseases. The increasing incidence of several diseases such as HIV, human papillomavirus, cancer, and chronic diseases is driving the market growth. For instance, according to the CDC, 1.1 million people aged 13 years and above were diagnosed to have HIV infection in the US in 2015. Similarly, in Asian countries like India in 2017, 0.20% of the population had HIV. In Japan, in 2017, 0.10% of the population was affected by HIV. In China, 664,751 people were diagnosed to have HIV in 2016, and 124,555 new HIV infection cases were reported. Furthermore, cancer is the second-leading cause of death worldwide. According to Our World in Data, in 2016, 8.9 million people were estimated to have died from cancer. In addition, as per the NIH, in 2017, 15,270 children and adolescents aged 0-19 years were diagnosed with cancer. In 2018, 1,735,350 new cases of cancer were diagnosed in the US, and around 609,640 patients died from the disease. Furthermore, the prevalence of chronic diseases such as Alzheimer’s disease, asthma, diabetes, multiple sclerosis, and chronic obstructive pulmonary disease has increased worldwide. Various therapeutic vaccines are used for the treatment of these diseases. Therefore, the increase in the prevalence of cancer and other diseases will drive market growth during the forecast period. 

Key Therapeutic Vaccines Market Challenge

The high cost of developing therapeutic vaccines will be a major challenge for the market during the forecast period. Vaccines are a potential tool to prevent and cure severe diseases. The development of vaccines to treat diseases requires significant investments, which is a challenge to the growth of the market. The cost of developing a single vaccine, from pre-clinical trials to the end of Phase IIa, can range between USD 31 million and USD 68 million, assuming no risk of failure. The development of a new vaccine candidate is estimated to cost more than USD 500 million, with further expenses required to establish facilities and equipment, which can range between USD 50 million and USD 700 million. The cost of a successful candidate could range between USD 319 million and USD 469 million. Some costs associated with vaccine development cannot be neglected to ensure adherence to the required safety standards. The US FDA approved the first therapeutic vaccine in April 2010. PROVENGE (sipuleucel-T) by Dendreon Corp. (Dendreon), a subsidiary of Sanpower Group, showed that it could extend life for about four months in men with a certain type of metastatic prostate cancer. However, the cost of PROVENGE treatment is USD 93,000 in the US. Therefore, the high cost of developing therapeutic vaccines may pose a challenge to the growth of the market. 

Therapeutic Vaccines Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the therapeutic vaccines market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Who are the Major Therapeutic Vaccines Market Vendors?

Aimmune Therapeutics Inc. - AR101: It is an oral immunotherapy drug under the Phase III stage of clinical trials to treat patients with peanut allergy.

The report analyzes the market’s competitive landscape and offers information on several market vendors, including: 

 

• Advantagene Inc.
• Aimmune Therapeutics Inc.
• Amgen Inc.
• Gilead Sciences Inc.
• Immune Response BioPharma Inc.
• Inovio Pharmaceuticals Inc.
• Merck & Co. Inc.
• Novartis AG
• Sanpower Group Co. Ltd.
• SOTIO AS

 

This statistical study of the market encompasses successful business strategies deployed by the key vendors. The market is concentrated and the vendors are deploying organic and inorganic growth strategies to compete in the market.

Which are the Key Regions for Therapeutic Vaccines Market?

For more insights on the market share of various regions Request PDF Sample now!

93% of the market’s growth will originate from North America during the forecast period. The US is the key market for therapeutic vaccines in North America. Market growth in this region will be slower than the growth of the market in the European regions.

The growing prevalence of various diseases is encouraging researchers to develop novel treatment therapies for these diseases. The development of novel therapies, such as therapeutic vaccines, will further drive market growth during the forecast period. Many vendors such as SELLAS, Immune Response BioPharma, Inovio Pharmaceuticals, and Advaxis Inc. (Advaxis) are headquartered in the US. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

What are the Revenue-generating Type Segments in the Therapeutic Vaccines Market?

To gain further insights on the market contribution of various segments Request a PDF Sample

The market share growth by the cancer vaccines segment will be significant during the forecast period. The cancer therapeutic vaccines segment is expected to exhibit accelerated growth momentum during the forecast period. This can be attributed to the increasing prevalence of cancer and the development of therapeutic vaccines to treat cancer. Cancer impacts individuals of all ages, sexes, and races. With the increasing prevalence of cancer, researchers are focusing on the development of cancer therapeutic vaccines as these vaccines are more effective than the current therapies available in the market.

This report provides an accurate prediction of the contribution of all the segments to the growth of the market size and actionable market insights on the post-COVID-19 impact on each segment.

Therapeutic Vaccines Market Scope
Report Coverage	Details
Page number	120
Base year	2019
Forecast period	2020-2024
Growth momentum & CAGR	Decelerate at a CAGR of 43%
Market growth 2020-2024	$ 3.78 billion
Market structure	Concentrated
YoY growth (%)	6.94
Regional analysis	North America, Europe, Asia, and ROW
Performing market contribution	North America at 93%
Key consumer countries	US, Germany, France, UK, and China
Competitive landscape	Leading companies, competitive strategies, consumer engagement scope
Companies profiled	Advantagene Inc., Aimmune Therapeutics Inc., Amgen Inc., Gilead Sciences Inc., Immune Response BioPharma Inc., Inovio Pharmaceuticals Inc., Merck & Co. Inc., Novartis AG, Sanpower Group Co. Ltd., and SOTIO AS
Market Dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, market condition analysis for the forecast period,
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this Therapeutic Vaccines Market Report?

• CAGR of the market during the forecast period 2020-2024
• Detailed information on factors that will drive market growth during the next five years
• Precise estimation of the market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behaviour
• The growth of the therapeutic vaccines industry across North America, Europe, Asia, and ROW
• A thorough analysis of the market’s competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch